<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01387906</url>
  </required_header>
  <id_info>
    <org_study_id>Latisse2010</org_study_id>
    <nct_id>NCT01387906</nct_id>
  </id_info>
  <brief_title>Latisse (Bimatoprost .03% Opthalmic Solution) for the Treatment of Hypotrichosis of the Eyebrows: Latisse Versus Placebo</brief_title>
  <official_title>Latisse(Bimatoprost .03% Opthalmic Solution) for the Treatment of Hypotrichosis of the Eyebrows: Latisse Versus Placebo</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kenneth Beer</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Beer, Kenneth R., M.D., PA</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to assess efficacy and safety of Latisse (bimatoprost
      .03% ophthalmic solution) applied to the lateral and medial eyebrows. The primary outcome is
      a increase in overall eyebrow prominence as measured by at least a 1-grade increase on the
      Global Eyebrow Assessment (GEyA) scale, from baseline to the end of the treatment which will
      be day 270 period.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2011</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">March 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy of Latisse applied to the lateral and medial eyebrow</measure>
    <time_frame>10 months</time_frame>
    <description>Increase in overall eyebrow prominence as measured by at least a 1-grade increase on the Global Eyebrow Assessment (GEyA) scale, from baseline to the end of the treatment which will be day 270 period.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Hypotrichosis</condition>
  <arm_group>
    <arm_group_label>Topical bimatoprost for eyebrows</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Topical bimatoprost will be applied to areas of the eyebrow that have diminished eyebrows (hypotrichosis).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>topical bimatoprost</intervention_name>
    <description>topical bimatoprost will be applied one drop to each eyebrow each night.</description>
    <arm_group_label>Topical bimatoprost for eyebrows</arm_group_label>
    <other_name>bimatoprost, Latisse, eyebrows</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Outpatient, female/male subjects of any race, 18-75 years of age.

          -  Subjects of childbearing potential must have a negative urine pregnancy test result at
             Baseline and practice a reliable method of contraception throughout the study

          -  Patients with hypotrichosis (thinning) of the eyebrows with a GEyA score of 1 or 2.

          -  Patient agrees to abstain from any treatment to the eyebrows including: waxing,
             plucking, threading, laser hair removal, and/or bleaching (excluding the glabella
             region).

          -  Able to understand the requirements of the study and sign Informed Consent/HIPAA
             Authorization forms.

          -  Written informed consent and written authorization for use or release of health and
             research information obtained.

          -  Willing to complete all required study visits, procedures, and evaluations including
             photography.

        Exclusion Criteria:

          -  Subjects who are pregnant (positive urine pregnancy test), planning to become
             pregnant, breast-feeding, or who are of childbearing potential and not practicing a
             reliable method of birth control.

          -  Patients with any uncontrolled systemic disease

          -  Patient with any known disease or abnormality of the eyebrows including eczema and
             seborrheic dermatitis

          -  Patients with known or suspected trichotillomania disorder

          -  Patients with a history of glaucoma and/or increased ocular pressure

          -  Patients who are currently using an IOP-lowering prostaglandin analog (including
             Lumigan)

          -  Patients with a known hypersensitivity to bimatoprost or any other ingredient in
             Latisse

          -  Previous cosmetic surgery to the upper face (e.g., periorbital surgery, brow lift,
             eyelid or eyebrow surgery, etc.).

          -  Patients with permanent eye and/or eyebrow make-up

          -  Any eyebrow tint or dye applications within 2 months prior to study entry

          -  Any planned facial cosmetic procedure that would interfere with the evaluation of the
             eyebrows

          -  Participation in another investigational drug or device study within the last 30 days
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kenneth Beer, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beer, Kenneth R., M.D., PA</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kenneth R. Beer, M.D. ,PA</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.palmbeachcosmetic.com</url>
    <description>eyebrows, bimatoprost, hypotrichosis</description>
  </link>
  <reference>
    <citation>Law SK. Bimatoprost in the treatment of eyelash hypotrichosis. Clin Ophthalmol. 2010 Apr 26;4:349-58.</citation>
    <PMID>20463804</PMID>
  </reference>
  <reference>
    <citation>Bimatoprost 0.03% solution (latisse) for eyelash enhancement. Med Lett Drugs Ther. 2009 Jun 1;51(1313):43-4.</citation>
    <PMID>19478690</PMID>
  </reference>
  <verification_date>June 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 1, 2011</study_first_submitted>
  <study_first_submitted_qc>July 5, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 6, 2011</study_first_posted>
  <last_update_submitted>June 14, 2012</last_update_submitted>
  <last_update_submitted_qc>June 14, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 15, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Beer, Kenneth R., M.D., PA</investigator_affiliation>
    <investigator_full_name>Kenneth Beer</investigator_full_name>
    <investigator_title>Investigator</investigator_title>
  </responsible_party>
  <keyword>mild</keyword>
  <keyword>moderate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypotrichosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bimatoprost</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

